Liposomal Amikacin for Inhalation (LAI) for Nontuberculous Mycobacteria

PHASE2CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

April 19, 2012

Primary Completion Date

August 18, 2014

Study Completion Date

June 18, 2015

Conditions
Mycobacterium Infections, Nontuberculous
Interventions
DRUG

Liposomal amikacin for inhalation (LAI)

"* Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.~* 590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.~* Administration time is approximately 13 minutes.~* Liposomal amikacin for inhalation will be administered for 84 days in the double-blind, randomized portion of the study.~* Subjects can continue with 84 additional days of dosing in the open label extension."

DRUG

placebo

"* Placebo is provided as a sterile aqueous lipid dispersion for inhalation via nebulization.~* Administration procedures, volume and administration time are similar to LAI.~* Placebo will be administered for 84 days only during the double-blind, randomized portion of the study."

Trial Locations (19)

Unknown

Birmingham

Stanford

Denver

Washington D.C.

Gainesville

Miami

Tampa

Kansas City

Bethesda

Rochester

New York

Chapel Hill

Cleveland

Portland

Philadelphia

Charleston

Tyler

Milwaukee

Hamilton

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Insmed Incorporated

INDUSTRY

NCT01315236 - Liposomal Amikacin for Inhalation (LAI) for Nontuberculous Mycobacteria | Biotech Hunter | Biotech Hunter